Clinical Trials

Date: 2016-02-16

Type of information: Initiation of the trial

phase:

Announcement:

Company: Diamyd Medical (Sweden)

Product: Diamyd® combined with one or several GABA-related substances

Action mechanism:

Disease:

Therapeutic area:

Country:

Trial details:

Latest news:

• On February 16, 2016, Diamyd Medical announced that the Company has signed an agreement with Uppsala University and Uppsala University Hospital to conduct a clinical study with the diabetes vaccine Diamyd® combined with one or several GABA-related substances for which the stem cell researcher Professor Per-Ola Carlsson will be the Principal Investigator. The planned researcher-initiated combination study will be discussed with the Swedish Medical Products Agency this spring and is the first of its kind where GABA combined with the diabetes vaccine Diamyd® will play a large role in the treatment of type 1 diabetes patients who have had the disease for a longer period of time but still have some residual insulin secretion left. It differs thereby from other studies where the treatment usually is initiated early in the disease process. Professor Per-Ola Carlsson, stem cell researcher and endocrinologist at Uppsala University Hospital will be the Principal Investigator of the study, while Uppsala University will be represented by the GABA expert Professor Bryndis Birnir, who is also a member of Diamyd Medical’s Scientific Advisory Board. The intention is that the GABA-related molecules will support beta cell function and simultaneously decrease the autoimmune inflammation so that a fertile milieu is generated for the GAD-based Antigen Based Therapy Diamyd® to induce tolerance for a longer period of time.